These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21333438)

  • 1. Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo.
    Zhang Y; Wang C; Wang H; Wang K; Du Y; Zhang J
    Cancer Lett; 2011 May; 304(1):21-32. PubMed ID: 21333438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
    Yang YI; Kim JH; Lee KT; Choi JH
    Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
    Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
    Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
    Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
    Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
    Zhu X; Sui M; Fan W
    Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gotlieb WH; Bruchim I; Gu J; Shi Y; Camirand A; Blouin MJ; Zhao Y; Pollak MN
    Gynecol Oncol; 2006 Feb; 100(2):389-96. PubMed ID: 16300820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protoapigenone, a novel flavonoid, inhibits ovarian cancer cell growth in vitro and in vivo.
    Chang HL; Su JH; Yeh YT; Lee YC; Chen HM; Wu YC; Yuan SS
    Cancer Lett; 2008 Aug; 267(1):85-95. PubMed ID: 18430509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
    Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
    Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced sensitivity of human ovarian carcinoma cell lines A2780 and A2780/CP to the combination of cisplatin and synthetic isothiocyanate ethyl 4-isothiocyanatobutanoate.
    Bodo J; Chovancova J; Hunakova L; Sedlak J
    Neoplasma; 2005; 52(6):510-6. PubMed ID: 16284698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide.
    Yang L; Mashima T; Sato S; Mochizuki M; Sakamoto H; Yamori T; Oh-Hara T; Tsuruo T
    Cancer Res; 2003 Feb; 63(4):831-7. PubMed ID: 12591734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.
    Chan DW; Liu VW; Tsao GS; Yao KM; Furukawa T; Chan KK; Ngan HY
    Carcinogenesis; 2008 Sep; 29(9):1742-50. PubMed ID: 18632752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein kinase C inhibitor Gö6976 augments caffeine-induced reversal of chemoresistance to cis-diamminedichloroplatinum-II (CDDP) in a human ovarian cancer model.
    Qamar L; Davis R; Anwar A; Behbakht K
    Gynecol Oncol; 2008 Sep; 110(3):425-31. PubMed ID: 18619662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel polysaccharide, isolated from Angelica sinensis (Oliv.) Diels induces the apoptosis of cervical cancer HeLa cells through an intrinsic apoptotic pathway.
    Cao W; Li XQ; Wang X; Fan HT; Zhang XN; Hou Y; Liu SB; Mei QB
    Phytomedicine; 2010 Jul; 17(8-9):598-605. PubMed ID: 20092988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro.
    Shi Y; Frankel A; Radvanyi LG; Penn LZ; Miller RG; Mills GB
    Cancer Res; 1995 May; 55(9):1982-8. PubMed ID: 7728769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo.
    Bardella C; Dettori D; Olivero M; Coltella N; Mazzone M; Di Renzo MF
    Clin Cancer Res; 2007 Apr; 13(7):2191-8. PubMed ID: 17404103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitory effect of tetrandrine on angiogenesis].
    Qian XP; Liu BR; Hu J; Li M; Hu WJ; Sun J; Yu LX
    Ai Zheng; 2008 Oct; 27(10):1050-5. PubMed ID: 18851784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.